Base de dados : LILACS
Pesquisa : E05.799.513.500 [Categoria DeCS]
Referências encontradas : 111 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 12 ir para página                         

  1 / 111 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-796894
Autor: Logghe, Pieter; Verlinde, Rolf; Bouttens, Frank; Van den Broecke, Caroline; Deman, Nathalie; Verboven, Koen; Maes, Dirk; Merckx, Luc.
Título: Long term outcome and side effects in patients receiving low-dose I125 brachytherapy: a retrospective analysis
Fonte: Int. braz. j. urol;42(5):906-917, Sept.-Oct. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objectives: To retrospectively evaluate the disease free survival (DFS), disease specific survival (DSS),overall survival (OS) and side effects in patients who received low-dose rate (LDR) brachytherapy with I125 stranded seeds. Materials and methods: Between july 2003 and august 2012, 274 patients with organ confined prostate cancer were treated with permanent I125 brachytherapy. The median follow-up, age and pretreatment prostate specific antigen (iPSA) was 84 months (12-120), 67 years (50-83) and 7.8 ng/mL (1.14-38), respectively. Median Gleason score was 6 (3-9). 219 patients (80%) had stage cT1c, 42 patients (15.3%) had stage cT2a, 3 (1.1%) had stage cT2b and 3 (1.1%) had stage cT2c. The median D90 was 154.3 Gy (102.7-190.2). Results: DSS was 98.5%.OS was 93.5%. 13 patients (4.7%) developed systemic disease, 7 patients (2.55%) had local progression. In 139 low risk patients, the 5 year biochemical freedom from failure rate (BFFF) was 85% and 9 patients (6.4%) developed clinical progression. In the intermediate risk group, the 5 year BFFF rate was 70% and 5 patients (7.1%) developed clinical progression. Median nPSA in patients with biochemical relapse was 1.58 ng/mL (0.21 – 10.46), median nPSA in patients in remission was 0.51 ng/mL (0.01 – 8.5). Patients attaining a low PSA nadir had a significant higher BFFF (p<0.05). Median D90 in patients with biochemical relapse was 87.2 Gy (51 – 143,1). Patients receiving a high D90 had a significant higher BFFF (p<0.05). Conclusion: In a well selected patient population, LDR brachytherapy offers excellent outcomes. Reaching a low PSA nadir and attaining high D90 values are significant predictors for a higher DFS.
Descritores: Neoplasias da Próstata/radioterapia
Braquiterapia/efeitos adversos
Radioisótopos do Iodo/administração & dosagem
Radioisótopos do Iodo/efeitos adversos
-Prognóstico
Neoplasias da Próstata/patologia
Reto/efeitos da radiação
Fatores de Tempo
Uretra/efeitos da radiação
Bexiga Urinária/efeitos da radiação
Modelos Logísticos
Estudos Retrospectivos
Fatores de Risco
Antígeno Prostático Específico/sangue
Medição de Risco
Relação Dose-Resposta à Radiação
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Idoso
Idoso de 80 Anos ou mais
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  2 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-777332
Autor: Prada, Pedro J; Anchuelo, Javier; Blanco, Ana García; Payá, Gema; Cardenal, Juan; Acuña, Enrique; Ferri, María; Vázquez, Andrés; Pacheco, Maite; Sanchez, Jesica.
Título: Low-dose-rate brachytherapy for patients with transurethral resection before implantation in prostate cancer. Long-term results
Fonte: Int. braz. j. urol;42(1):47-52, Jan.-Feb. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT We analyzed the long-term oncologic outcome for patients with prostate cancer and transurethral resection who were treated using low-dose-rate (LDR) prostate brachytherapy. Methods and Materials: From January 2001 to December 2005, 57 consecutive patients were treated with clinically localized prostate cancer. No patients received external beam radiation. All of them underwent LDR prostate brachytherapy. Biochemical failure was defined according to the "Phoenix consensus". Patients were stratified as low and intermediate risk based on The Memorial Sloan Kettering group definition. Results: The median follow-up time for these 57 patients was 104 months. The overall survival according to Kaplan-Meier estimates was 88% (±6%) at 5 years and 77% (±6%) at 12 years. The 5 and 10 years for failure in tumour-free survival (TFS) was 96% and respectively (±2%), whereas for biochemical control was 94% and respectively (±3%) at 5 and 10 years, 98% (±1%) of patients being free of local recurrence. A patient reported incontinence after treatment (1.7%). The chronic genitourinary complains grade I were 7% and grade II, 10%. At six months 94% of patients reported no change in bowel function.Conclusions: The excellent long-term results and low morbidity presented, as well as the many advantages of prostate brachytherapy over other treatments, demonstrates that brachytherapy is an effective treatment for patients with transurethral resection and clinical organ-confined prostate cancer
Descritores: Neoplasias da Próstata/cirurgia
Neoplasias da Próstata/radioterapia
Braquiterapia/métodos
Ressecção Transuretral da Próstata/métodos
-Prognóstico
Neoplasias da Próstata/mortalidade
Neoplasias da Próstata/patologia
Dosagem Radioterapêutica
Incontinência Urinária/etiologia
Braquiterapia/efeitos adversos
Reprodutibilidade dos Testes
Seguimentos
Antígeno Prostático Específico/sangue
Medição de Risco
Relação Dose-Resposta à Radiação
Estimativa de Kaplan-Meier
Radioisótopos do Iodo/uso terapêutico
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Idoso
Responsável: BR1.1 - BIREME


  3 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-840817
Autor: García-Sánchez, Cristina; Román Martín, Ana A; Conde-Sánchez, J. Manuel; Congregado-Ruíz, C. Belén; Osman-García, Ignacio; Medina-López, Rafael A.
Título: Comparative analysis of short - term functional outcomes and quality of life in a prospective series of brachytherapy and Da Vinci robotic prostatectomy
Fonte: Int. braz. j. urol;43(2):216-223, Mar.-Apr. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction There is a growing interest in achieving higher survival rates with the lowest morbidity in localized prostate cancer (PC) treatment. Consequently, minimally invasive techniques such as low-dose rate brachytherapy (BT) and robotic-assisted prostatectomy (RALP) have been developed and improved. Comparative analysis of functional outcomes and quality of life in a prospective series of 51BT and 42Da Vinci prostatectomies DV Materials and Methods Comparative analysis of functional outcomes and quality of life in a prospective series of 93 patients with low-risk localized PC diagnosed in 2011. 51patients underwent low-dose rate BT and the other 42 patients RALP. IIEF to assess erectile function, ICIQ to evaluate continence and SF36 test to quality of life wee employed. Results ICIQ at the first revision shows significant differences which favour the BT group, 79% present with continence or mild incontinence, whereas in the DV group 45% show these positive results. Differences disappear after 6 months, with 45 patients (89%) presenting with continence or mild incontinence in the BT group vs. 30 (71%) in the DV group. 65% of patients are potent in the first revision following BT and 39% following DV. Such differences are not significant and cannot be observed after 6 months. No significant differences were found in the comparative analysis of quality of life. Conclusions ICIQ after surgery shows significant differences in favour of BT, which disappear after 6 months. Both procedures have a serious impact on erectile function, being even greater in the DV group. Differences between groups disappear after 6 months.
Descritores: Prostatectomia/métodos
Neoplasias da Próstata/cirurgia
Neoplasias da Próstata/radioterapia
Qualidade de Vida
Braquiterapia/métodos
Procedimentos Cirúrgicos Robóticos/métodos
-Complicações Pós-Operatórias
Prostatectomia/efeitos adversos
Fatores de Tempo
Incontinência Urinária/etiologia
Índice de Gravidade de Doença
Braquiterapia/efeitos adversos
Estudos Prospectivos
Inquéritos e Questionários
Resultado do Tratamento
Relação Dose-Resposta à Radiação
Procedimentos Cirúrgicos Robóticos/efeitos adversos
Disfunção Erétil/etiologia
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  4 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-974950
Autor: Carvalho, Heloisa de Andrade; Villar, Rosangela Correa.
Título: Radiotherapy and immune response: the systemic effects of a local treatment
Fonte: Clinics;73(supl.1):e557s, 2018. tab, graf.
Idioma: en.
Resumo: Technological developments have allowed improvements in radiotherapy delivery, with higher precision and better sparing of normal tissue. For many years, it has been well known that ionizing radiation has not only local action but also systemic effects by triggering many molecular signaling pathways. There is still a lack of knowledge of this issue. This review focuses on the current literature about the effects of ionizing radiation on the immune system, either suppressing or stimulating the host reactions against the tumor, and the factors that interact with these responses, such as the radiation dose and dose / fraction effects in the tumor microenvironment and vasculature. In addition, some implications of these effects in cancer treatment, mainly in combined strategies, are addressed from the perspective of their interactions with the more advanced technology currently available, such as heavy ion therapy and nanotechnology.
Descritores: Radiação Ionizante
Radioterapia/efeitos adversos
Sistema Imunitário/efeitos da radiação
Neoplasias/imunologia
Neoplasias/radioterapia
-Radioterapia/tendências
Morte Celular/efeitos da radiação
Apoptose/efeitos da radiação
Apoptose/imunologia
Relação Dose-Resposta à Radiação
Imunoterapia/métodos
Imunoterapia/tendências
Necrose/etiologia
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  5 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1056339
Autor: Viani, Gustavo; Hamamura, Ana Carolina; Faustino, Alexandre C.
Título: Intensity modulated radiotherapy (IMRT) or conformational radiotherapy (3D-CRT) with conventional fractionation for prostate cancer: Is there any clinical difference?
Fonte: Int. braz. j. urol;45(6):1105-1112, Nov.-Dec. 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: To compare the treatment outcomes of a cohort of prostate cancer patients treated with conventional schedule using IMRT or 3DRT technique. Materials and Methods: Between 2010-2017, 485 men with localized prostate cancer were treated with conventional radiotherapy schedule with a total dose ≥74Gy using IMRT (231) or 3DCRT (254). Late gastrointestinal (GI) and genitourinary (GU) toxicity were retrospectively evaluated according to modified RTOG criteria. The biochemical control was defined by the Phoenix criteria (nadir + 2ng/mL). The comparison between the groups included biochemical recurrence free survival (bRFS), overall survival (OS) and late toxicity. Results: With a median follow-up of 51 months (IMRT=49 and 3DRT=51 months), the maximal late GU for >=grade- 2 during the entire period of follow-up was 13.1% in the IMRT and 15.4% in the 3DRT (p=0.85). The maximal late GI ≥ grade- 2 in the IMRT was 10% and in the 3DRT 24% (p=0.0001). The 5-year bRFS for all risk groups with IMRT and 3D-CRT was 87.5% vs. 87.2% (p=0.415). Considering the risk-groups no significant difference for low-, intermediate- and high-risk groups between IMRT (low-95.3%, intermediate-86.2% and high-73%) and 3D-CRT (low-96.4%, intermediate-88.2% and high-76.6%, p=0.448) was observed. No significant differences for OS and DMFS were observed comparing treatment groups. Conclusion: IMRT reduces significantly the risk of late GI severe complication compared with 3D-CRT using conventional fractionation with a total dose ≥74Gy without any differences for bRFS and OS.
Descritores: Neoplasias da Próstata/radioterapia
Radioterapia Conformacional/métodos
Radioterapia de Intensidade Modulada/métodos
-Neoplasias da Próstata/mortalidade
Neoplasias da Próstata/patologia
Lesões por Radiação
Dosagem Radioterapêutica
Fatores de Tempo
Sistema Urogenital/efeitos da radiação
Estudos Retrospectivos
Fatores de Risco
Medição de Risco
Intervalo Livre de Doença
Radioterapia Conformacional/efeitos adversos
Trato Gastrointestinal/efeitos da radiação
Relação Dose-Resposta à Radiação
Radioterapia de Intensidade Modulada/efeitos adversos
Estimativa de Kaplan-Meier
Gradação de Tumores
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Idoso
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  6 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1001356
Autor: Constanzo, Felipe; Silva, Rodrigo Souza da; de Almeida, Daniel Benzecry; Ferragut, Maria Alice; Coelho Neto, Mauricio; Toledo, Hugo Veroneze; Ramina, Ricardo.
Título: Gamma knife radiosurgery for trigeminal neuralgia: first case series from Latin America / Radiocirurgia por gamma knife para tratamento da neuralgia do trigêmeo: primeira série de casos na América Latina
Fonte: Arq. neuropsiquiatr;77(4):232-238, Apr. 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Gamma Knife® radiosurgery (GKRS) for trigeminal neuralgia is an effective treatment with at least a 50% reduction of pain in 75-95% of patients. Objective: To present the first series of patients treated for trigeminal neuralgia using GKRS in Latin America. Methods: Retrospective analysis. Analysis consisted of time to improvement of symptoms, best Barrow Neurological Institute scale (BNI) score after procedure, time without pain, time to recurrence and post-procedural hypoesthesia. Results: Nineteen cases of classical trigeminal neuralgia were analyzed and three cases of symptomatic trigeminal neuralgia were described. Mean time from symptom onset to radiosurgery was 99.6 months, and 78.9% of patients had undergone invasive procedures before treatment. Patients were followed for a mean of 21.7 months. BNI I was achieved in 36.8%, IIIa in 21.1%, IIIb in 21.1%, IV in 5.3% and V in 15.7%. New hypoesthesia developed in 12.1% patients, which was associated with achieving BNI I after the procedure (p < 0.05). Time from diagnosis to GKRS was higher in patients who failed to achieve BNI I (143 vs. 76 months). The distance from the root entry zone in patients who achieved BNI I was greater than patients who did not (1.94 vs. 1.14 mm). Mean distance from the root entry zone in patients with new hypoesthesia was 2.85 mm vs. 1.06 mm (p = 0.06). Conclusion: Clinical response to GKRS is related to the time between diagnosis and procedure, thus its indication should be considered early in the management of these patients.

RESUMO A radiocirurgia por Gamma Knife (GKRS) para neuralgia do trigêmeo é um tratamento comprovado, com redução de pelo menos 50% da dor em 75-95% dos casos. Objetivo: Apresentar a primeira série de pacientes tratados por neuralgia do trigêmeo com GKRS na America Latina. Métodos: Análise retrospectiva. A análise consistiu no tempo até melhora do sintoma, melhor escala do Barrow Neurological Institute (BNI) depois do procedimento, tempo sem dor, tempo até recorrência e hipoestesia pós-procedimento. Resultados: Dezenove casos de neuralgia do trigêmeo clássica foram analisados e três casos de neuralgia do trigêmeo sintomática foram descritos. Tempo médio entre começo dos sintomas e GKRS foi de 99,6 meses e 78,9% dos pacientes já tinham sido submetidos a procedimento invasivo prévio. O tempo de acompanhamento médio foi de 21,7 meses. BNI I foi conseguido em 36,8%, IIIa em 21,1%, IIIb em 21,1%, IV em 5,3% e V em 15,7%. Nova hipoestesia apareceu em 12,1% dos casos, o que foi associado a conseguir BNI I pós-procedimento (p < 0,05). Tempo desde o diagnóstico até GKRS foi maior em pacientes que não conseguiram BNI I (143 vs. 76 meses). Distância da zona de entrada do nervo em pacientes que conseguiram BNI I foi maior (1,94 vs. 1,14mm). Distância do zona de entrada do nervo em pacientes com nova hipoestesia foi de 2,85mm vs. 1,06mm (p = 0,06) Conclusão: A resposta à GKRS está relacionada ao tempo entre diagnóstico e procedimento, pelo que a indicação de GKRS deve ser considerada cedo no tratamento desses pacientes.
Descritores: Neuralgia do Trigêmeo/radioterapia
Radiocirurgia/métodos
-Recidiva
Fatores de Tempo
Medição da Dor
Reprodutibilidade dos Testes
Estudos Retrospectivos
Seguimentos
Resultado do Tratamento
Rizotomia/métodos
Relação Dose-Resposta à Radiação
América Latina
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Responsável: BR1.1 - BIREME


  7 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-973869
Autor: Bravo-Filho, Vasco; Logan, Patrick; Zoroquiain, Pablo; Aldrees, Sultan; Vilà, Natàlia; Oweida, Ayman; Belfort Neto, Rubens; Burnier Jr, Miguel N.
Título: Effects of ranibizumab and amfenac on the functional abilities and radiosensitivity of uveal melanoma cells / Efeitos do ranibizumabe e do amfenac nas habilidades funcionais e na radiossensibilidade de células de melanoma uveal
Fonte: Arq. bras. oftalmol;82(1):38-44, Jan.-Feb. 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: To evaluate the effects of ranibizumab and amfenac in human uveal melanoma cell lines and to explore the ability of these compounds to sensitize uveal melanoma cells to radiation therapy. Methods: The 92.1 human uveal melanoma cell line was cultured and subjected to the proposed treatment (ranibizumab, amfenac, and a combination of both). Proliferation, migration, and invasion assays of the 92.1 uveal melanoma cell line were assessed after pretreatment with ranibizumab (125 mg/mL), amfenac (150 nM), or a combination of both. In addition, proliferation rates were assessed after treatment with ranibizumab and amfenac, and the cells were subsequently exposed to various radiation doses (0, 4, and 8 Gy). Results: Proliferation assay: cells treated with a combination of ranibizumab and amfenac had lower proliferation rates than controls (p=0.016) and than those treated with only ranibizumab (p=0.033). Migration assay: a significantly lower migration rate was observed in cells treated with amfenac than the control (p=0.014) and than those treated with ranibizumab (p=0.044). Invasion assay: there were no significant differences among the studied groups. Irradiation exposure: in the 4 Gy dose group, there were no significant differences among any groups. In the 8 Gy dose group, treatment with ranibizumab, amfenac, and their combination prior to application of the 8 Gy radiation led to a marked reduction in proliferation rates (p=0.009, p=0.01, and p=0.034, respectively) compared with controls. Conclusion: Combination of ranibizumab and amfenac reduced the proliferation rate of uveal melanoma cells; however, only amfenac monotherapy significantly decreased cell migration. The radiosensitivity of the 92.1 uveal melanoma cell line increased following the administration of ranibizumab, amfenac, and their combination. Further investigation is warranted to determine if this is a viable pretreatment strategy to render large tumors amenable to radiotherapy.

RESUMO Objetivo: Avaliar os efeitos do ranibizumabe em associação com o amfenac nas células de melanoma uveal humano e explorar a capacidade desses compostos em sensibilizar as células de melanoma uveal à radioterapia. Métodos: Células de melanoma uveal humano do tipo 92.1 foram cultivadas e submetidas ao tratamento proposto (ranibizumabe, amfenac e a combinação de ambos). Ensaios de proliferação, migração e invasão com as células de melanoma uveal do tipo 92.1 foram avaliados após tratamento com ranibizumabe (125 mg/ml), amfenac (150 nM) e a combinação de ambos. Além disso, as taxas de proliferação foram avaliadas após tratamento com ranibizumabe e amfenac com subsequente exposição das células a diferentes doses de radiação (0 Gy, 4 Gy e 8 Gy). Resultados: Ensaio de proliferação: células tratadas com ranibizumabe e amfenac combinados apresentaram taxas de proliferação inferiores em comparação ao grupo controle (p=0,016), do que as tratadas apenas com ranibizumabe (p=0,033). Ensaio de migração: foi observada uma taxa de migração significativamente mais baixa nas células tratadas com amfenac do que no grupo controle (p=0,014) e do que nas tratadas com ranibizumabe (p=0,044). Ensaio de invasão: não houve diferenças significativas entre os grupos estudados. Exposição à irradiação: no grupo da dose de 4 Gy, não houve diferença significante entre os grupos. No grupo da dose de 8 Gy, o tratamento com ranibizumabe, afenac e sua combinação antes da aplicação da radiação de 8 Gy levou a uma redução acentuada nas taxas de proliferação (p=0,009, p=0,01 e p=0,034, respectivamente) em comparação aos grupos controle. Conclusão: A combinação de ranibizumabe e amfenac reduziu a taxa de proliferação das células de melanoma uveal; no entanto, apenas o amfenac diminuiu significativamente a migração celular. A radiossensibilidade das células de melanoma uveal do tipo 92.1 aumentou após a administração de ranibizumabe, amfenac e sua combinação. Mais investigações são necessárias para determinar se esta é uma estratégia de pré-tratamento viável para tornar grandes tumores passíveis de radioterapia.
Descritores: Fenilacetatos/farmacologia
Inibidores da Angiogênese/farmacologia
Inibidores de Ciclo-Oxigenase 2/farmacologia
Ranibizumab/farmacologia
Melanoma/tratamento farmacológico
Melanoma/radioterapia
-Tolerância a Radiação
Neoplasias Uveais/tratamento farmacológico
Neoplasias Uveais/radioterapia
Protocolos de Quimioterapia Combinada Antineoplásica
Movimento Celular/efeitos dos fármacos
Movimento Celular/efeitos da radiação
Reprodutibilidade dos Testes
Linhagem Celular Tumoral
Proliferação de Células/efeitos dos fármacos
Proliferação de Células/efeitos da radiação
Relação Dose-Resposta à Radiação
Limites: Humanos
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  8 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Amaral, Ademir
Texto completo
Id: biblio-886652
Autor: SANTOS, NEYLIANE F G DOS; SILVA, RAFAEL F; PINTO, MARCELA M P L; SILVA, EDVANE B DA; TASAT, DEBORAH R; AMARAL, ADEMIR.
Título: Active caspase-3 expression levels as bioindicator of individual radiosensitivity
Fonte: An. acad. bras. ciênc;89(1,supl):649-659, May. 2017. graf.
Idioma: en.
Resumo: ABSTRACT Several molecules and events involved in cell response to radiation-induced damage have been investigated towards a personalized radiotherapy. Considering the importance of active caspase-3 in the proteolytic cascade that ensures radiation-induced apoptosis execution, this research was designed to evaluate the expression levels of this protein as a bioindicator of individual radiosensitivity. Peripheral blood samples of 10 healthy individuals were gamma-irradiated (cobalt-60 source) with 1, 2 and 4 Gy (control: non-irradiated samples), and active caspase-3 expression levels were measured in lymphocytes, by flow cytometry, ex vivo and after different times of in vitro incubation (24, 48 and 72 hours). Short-term incubation of 24 h was the most adequate condition to evidence correlations between dose radiation and active caspase-3 expression. For each radiation dose, it was observed a significant inter-individual variation in active caspase-3 expression intensity, suggesting that this parameter may be suitable for evidence individual radiosensitivity. The methodology presented and discussed in this work may help to predict healthy tissues response to radiation exposure toward the better patient outcome.
Descritores: Tolerância a Radiação/efeitos da radiação
Linfócitos/efeitos da radiação
Radioisótopos de Cobalto
Apoptose/efeitos da radiação
Caspase 3/metabolismo
-Linfócitos/enzimologia
Biomarcadores Ambientais
Relação Dose-Resposta à Radiação
Citometria de Fluxo
Limites: Humanos
Masculino
Feminino
Adulto
Responsável: BR1.1 - BIREME


  9 / 111 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-886733
Autor: LOPES, AMANDA M; BOBROWSKI, VERA L; SILVA, SERGIO D DOS ANJOS E; DEUNER, SIDNEI.
Título: Morphophysiological and biochemical alterations in Ricinus communis L. seeds submitted to cobalt60 gamma radiation
Fonte: An. acad. bras. ciênc;89(3):1925-1933, July-Sept. 2017. graf.
Idioma: en.
Resumo: ABSTRACT This study aimed to evaluate the radiosensitivity of castor bean seeds after applications of different doses of Cobalt60 gamma radiation. Seeds were pre-soaked for 24 hours in distilled water and then irradiated with 50, 100, 150, and 200 Gy, except the control. Sowing was performed in trays, which contained soil as substrate and were maintained in a greenhouse. The electrical conductivity, emergence, emergence speed index, growth parameters and activities of antioxidant enzymes (superoxide dismutase, ascorbate peroxidase, and catalase) were evaluated in the leaves and roots of castor bean seedlings. Gamma radiation did not affect the electrical conductivity of the seeds; however, at a dose of 200 Gy, the emergence and emergence speed index of the seedlings was negatively affected. An analysis of the morphophysiological parameters revealed a reduction in seedling size as the radiation dose increased. There was a significant increase in superoxide dismutase and ascorbate peroxidase activities at higher radiation doses in the leaves, but not in roots. Thus, the analysis of all the variables suggests a response pattern as to the morphophysiological and biochemical changes of castor bean seedlings due to the increase of gamma radiation, which may serve as a tool for generating greater genetic variability.
Descritores: Ricinus/efeitos da radiação
Sementes/efeitos da radiação
Radioisótopos de Cobalto
Germinação/efeitos da radiação
Raios gama
-Ricinus/crescimento & desenvolvimento
Sementes/crescimento & desenvolvimento
Relação Dose-Resposta à Radiação
Responsável: BR1.1 - BIREME


  10 / 111 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Boscolo, Frab Norberto
Texto completo
Id: lil-781761
Autor: Nejaim, Yuri; Vasconcelos, Karla de Faria; Roque-Torres, Gina D; Meneses-López, Abraham; Bóscolo, Frab Norberto; Haiter-Neto, Francisco.
Título: Racionalización de la dosis de radiación / Streamlining the radiation dose
Fonte: Rev. estomatol. Hered;25(3):238-245, jul.-sept. 2015. tab.
Idioma: es.
Resumo: En la actualidad existe una gran aceptación por la medicina y la odontología, en que la práctica clínica debe ser ôbasada en evidencia científicaõ, tanto como sea posible. Es por eso que múltiples trabajos se han publicado orientados a disminuir las dosis de radiación en los diferentes tipos de modalidades imaginológicas usados en la odontología, ya que el mayor efecto de las radiaciones, sobre todo en niños, nos obliga a tomar medidas necesarias para racionalizar su uso, especialmente con la tomografía computarizada Cone Beam (TCCB), método que aporta las mayores dosis en la odontología. Esta revisión fue escrita utilizando un enfoque de este tipo con el propósito de racionalizar la dosis de radiación en nuestros pacientes. El equipo del proyecto SEDENTEXCT recopiló y analizó relevantes publicaciones en la literatura, pautas que han demostrado su eficacia en el pasado, para llegar a formular recomendaciones que contribuyan a la optimización del uso de las radiaciones ionizantes en la odontología, ayudando de esa manera a ver con otros ojos la dosis recibida por los pacientes, y con la presente se recomienda tener en cuenta dicho documento para poder prescribir de manera más adecuada los exámenes complementarios que usamos diariamente...

There is now wide acceptance in medicine and dentistry that clinical practice should be as ôevidence-basedõ as possible. Which is why many works have been published aimed at reducing radiation doses in different types of imaging modalities in dentistry, and that the major effect of radiation especially in children requires us to take necessary steps to rationalize their use especially the Cone Beam Computed Tomography (CBCT) method that provides the highest doses in dentistry. This review was written using this approach because of the purpose of streamlining the radiation dose in our patients. SEDENTEXCT team collected and analyzed relevant publications in the literature, guidelines that have proven effective in the past to reach recommendations, which can contribute to optimizing the use of ionizing radiation in dentistry, helping to see with others eyes the dose received by our patients. This paper recommend to consider the SEDENTEXCT project to prescribe more appropriately complementary exams we use daily...
Descritores: Radiação Ionizante
Relação Dose-Resposta à Radiação
Limites: Humanos
Tipo de Publ: Revisão
Responsável: PE1.1 - Oficina Universitária de Biblioteca



página 1 de 12 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde